Ep. 206 - Roche, AbbVie Deals; Plus: FDA & CAR T

from BioCentury This Week · host BioCentury

Biopharma’s latest pair of multibillion-dollar takeouts come in two of industry’s hottest areas: ADCs and obesity. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the move by Roche into obesity via its acquisition of Carmot Therapeutics and the winding journey of ADC company ImmunoGen to its $10.1 billion buyout by AbbVie. BioCentury’s editors discuss what FDA’s statement on the risk of T cell malignancy following BCMA- or CD19-directed CAR T cell therapy means for companies operating in the space.Reach us by sending a text

Episode metadata supplied by the publisher feed · Published Dec 5, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Ep. 206 - Roche, AbbVie Deals; Plus: FDA & CAR T

0:00 19:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioCentury This Week?

This episode is 19 minutes long.

When was this BioCentury This Week episode published?

This episode was published on December 5, 2023.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!